ContraFect Corporation (CFRXQ)

OTCMKTS · Delayed Price · Currency is USD
0.0000
0.00 (0.00%)
At close: Mar 24, 2026
-99.00%
Market Cap 11.00
Revenue (ttm) n/a
Net Income (ttm) -24.14M
Shares Out 10.70M
EPS (ttm) -5.58
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 200
Average Volume 21,509
Open 0.0000
Previous Close 0.0000
Day's Range 0.0000 - 0.0000
52-Week Range n/a
Beta -9.21
RSI 38.72
Earnings Date n/a

About ContraFect

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator as... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 23
Stock Exchange OTCMKTS
Ticker Symbol CFRXQ
Full Company Profile

Financial Performance

News

There is no news available yet.